Top Story Today
The First Drug to Make Platinum Chemo Optional in Lung Cancer
Merck and Kelun-Biotech's antibody-drug conjugate sac-TMT just became the first therapy to replace platinum chemotherapy in frontline lung cancer across two Phase 3 trials. The drug, a guided missile that locks onto TROP2 proteins on tumor cells and delivers a toxic payload inside, beat both Keytruda alone (in PD-L1-positive patients) and the gold-standard Keytruda-plus-chemo combo (in PD-L1-negative patients). Twelve-month overall survival hit 80.4% versus 68.9% for Keytruda monotherapy. The timing is brutal for Pfizer, whose own ADC recently failed a lung cancer trial after the company spent $43 billion acquiring Seagen's platform.
Why it matters: Wall Street analysts called this the first direct proof that an ADC can replace platinum chemo in first-line lung cancer, a structural shift in how we treat the disease responsible for more cancer deaths than any other. If overall survival data hold up, the platinum backbone that's anchored oncology for decades could become optional.
Read more →Funding and Financings
A Professor's Friends Just Funded the Biggest Biotech IPO Ever
Parabilis Medicines raised $670 million in the largest biotech IPO on record, topping Moderna's 2018 debut. Shares jumped 58% on day one. The company started with zero venture capital, funded by wealthy friends of Harvard chemist Gregory Verdine (the original company name, FogPharma, literally stood for "Friends of Greg"). Regeneron bought $75 million in a concurrent placement, bringing total IPO-week capital to roughly $745 million.
Read more →$715 Million in 48 Hours: AI Drugs and Radioactive Cancer Killers
AI drug discovery firm Chai Discovery closed a $400 million Series C (valued at $3.8 billion), and radiopharmaceutical developer AdvanCell followed the next day with a $315 million Series D. Chai's platform delivers antibody hit rates roughly 100x better than previous methods; AdvanCell's lead drug showed an 80% response rate in prostate cancer. Both rounds were oversubscribed, spotlighting biotech's two hottest investment themes.
Read more →Regulatory and Legal
Three Strikes, All Manufacturing: A Liver Cancer Drug That Works But Can't Get Approved
The FDA rejected Hengrui and Elevar's liver cancer combo for the third consecutive time, and the agency has never once questioned whether the drug works. The first two rejections cited factory problems at the camrelizumab plant in Suzhou; the third flagged a completely different facility making rivoceranib. Parent company HLB reportedly plunged to limit-down on the news. About 74% of recent FDA rejections involve manufacturing issues, making this a cautionary tale for every biotech relying on overseas production.
Read more →Supreme Court Pulls the Rug Out From 60,000 Roundup Cancer Lawsuits
In a 7-2 ruling, the Supreme Court decided that federal pesticide law blocks most state-court failure-to-warn claims against Roundup, potentially wiping out roughly 60,000 pending lawsuits. Since the EPA concluded glyphosate is "not likely to be carcinogenic," state juries can't override that call. Bayer has already paid $11 billion in settlements; the ruling establishes a powerful preemption precedent that agrochemical and pharmaceutical companies will be eager to borrow.
Read more →Clinical Milestones
The Heartburn Drug That Just Unlocked 60 Million New Patients
Phathom's Voquezna became the first and only drug with an FDA label for non-erosive GERD, the most common form of heartburn accounting for 50-70% of all cases. PPIs work for just 37% of these patients; Voquezna delivered 45% heartburn-free days versus 28% for placebo. Revenue already tripled to $175 million in 2025, and Phathom is guiding toward $1 billion in peak sales with no generic competition expected before 2033.
Read more →Vitiligo Gets a New Oral Challenger as InnoCare's TYK2 Inhibitor Delivers
InnoCare's oral TYK2 inhibitor soficitinib hit its primary endpoint in a Phase II vitiligo trial, with the 120 mg dose delivering 41.2% facial repigmentation versus 2.2% for placebo (p < 0.0001). InnoCare now has a slight data edge over Takeda's competing program. The trial rolls directly into Phase III with a higher bar: 75% repigmentation at one year.
Read more →